Moderna, Inc. (MRNA)
61.82
-1.33
(-2.11%)
USD |
NASDAQ |
Jul 17, 16:00
61.70
-0.12
(-0.19%)
After-Hours: 20:00
Moderna PS Ratio : 10.87 for July 17, 2026
PS Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PS Ratio Data
| Date | Value |
|---|---|
| July 17, 2026 | 10.87 |
| July 16, 2026 | 11.10 |
| July 15, 2026 | 12.01 |
| July 14, 2026 | 11.86 |
| July 13, 2026 | 11.78 |
| July 10, 2026 | 12.00 |
| July 09, 2026 | 13.46 |
| July 08, 2026 | 12.98 |
| July 07, 2026 | 14.03 |
| July 06, 2026 | 14.38 |
| July 02, 2026 | 14.03 |
| July 01, 2026 | 12.75 |
| June 30, 2026 | 12.31 |
| June 29, 2026 | 12.26 |
| June 26, 2026 | 11.83 |
| June 25, 2026 | 10.51 |
| June 24, 2026 | 10.62 |
| June 23, 2026 | 10.73 |
| June 22, 2026 | 10.44 |
| June 18, 2026 | 11.25 |
| June 17, 2026 | 10.87 |
| June 16, 2026 | 9.742 |
| June 15, 2026 | 9.167 |
| June 12, 2026 | 8.776 |
| June 11, 2026 | 8.729 |
| Date | Value |
|---|---|
| June 10, 2026 | 8.087 |
| June 09, 2026 | 8.393 |
| June 08, 2026 | 8.370 |
| June 05, 2026 | 8.342 |
| June 04, 2026 | 9.072 |
| June 03, 2026 | 8.627 |
| June 02, 2026 | 8.026 |
| June 01, 2026 | 8.099 |
| May 29, 2026 | 8.298 |
| May 28, 2026 | 8.365 |
| May 27, 2026 | 8.372 |
| May 26, 2026 | 8.270 |
| May 22, 2026 | 8.244 |
| May 21, 2026 | 8.310 |
| May 20, 2026 | 8.462 |
| May 19, 2026 | 8.040 |
| May 18, 2026 | 8.460 |
| May 15, 2026 | 8.623 |
| May 14, 2026 | 8.797 |
| May 13, 2026 | 8.866 |
| May 12, 2026 | 9.367 |
| May 11, 2026 | 9.299 |
| May 08, 2026 | 9.557 |
| May 07, 2026 | 8.535 |
| May 06, 2026 | 8.579 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| BioNTech SE | 6.857 |
| Kailera Therapeutics, Inc. | -- |
| Replimune Group, Inc. | -- |
| Sarepta Therapeutics, Inc. | 0.8546 |
| Erasca, Inc. | -- |
PS Ratio Related Metrics
| Price to Book Value | 3.313 |
| Price | 61.82 |
| Earnings Yield | -13.18% |
| Market Cap | 24.54B |